Zenas Biopharma posts corporate presentation on autoimmune disease pipeline, led by obexelimab program - ZBIO News | RalliesZenas Biopharma posts corporate presentation on autoimmune disease pipeline, led by obexelimab program
Z
ZBIO• Corporate presentation highlights autoimmune disease pipeline
- Zenas Biopharma outlined a near-term regulatory path for obexelimab in IgG4-RD, with an FDA decision expected by May 2027.
- Phase 3 INDIGO in IgG4-RD met its primary endpoint, cutting flare risk 56% versus placebo; 73% of treated patients were flare-free.
- Key secondary endpoints favored obexelimab, including 37.1% complete remission at week 52 versus 19.6% for placebo.
- Orelabrutinib, a BTK inhibitor, is in Phase 3 for PPMS and naSPMS, with trials initiated in 3Q 2025 and 1Q 2026.
- Pipeline updates flagged clinical data expected by year-end 2026 for oral IL-17 inhibitor ZB021, with additional readouts in 2027 for ZB022 and ZB014.
DUKR
•
